Postoperative Patient Articles & Analysis
10 news found
“We continue to be encouraged by the potential of LB1148 to protect gastrointestinal integrity and accelerate the return of postoperative GI function. Based on the positive data to-date, we believe LB1148 has the potential to truly establish the standard of care and provide hospitals with a potentially safe solution to accelerate patient discharge. ...
Evidence suggests that the release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and the formation of postoperative adhesions. By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to the return of normal GI function, and shorten the duration of costly ...
“There is a significant unmet need to prevent adhesions with almost seven million surgeries each year in the U.S. where patients are at risk for postoperative adhesions. Adhesions can be found in up to 90% of cases after intra-abdominal surgery. Some patients will suffer life-long complications, and it’s also estimated that the US ...
Long term outcomes data will be collected to assess the role of aprevo® devices in improving patient outcomes and reducing postoperative complications. "Our partnership with the ISSGF and the inclusion of aprevo in the Complex Adult Deformity Surgery (CADS) clinical study demonstrates the importance of clinical data collection in the treatment of ...
Therefore, we asked the CARMAT team to join our forces for this ultima ratio use in order to face that critical situation of our patient. Unfortunately, because of its terminally ill status and the extremely fragile clinical profile, the patient passed away in the postoperative course. However, we observed that Aeson® has been able to ...
ByCarmat
Continued evolution of EndoGastric Solutions’ EsophyX technology and concomitant use of TIF 2.0 with hiatal hernia repair brings long-term GERD relief to a broader spectrum of patients REDMOND, Wash – June 17, 2020 – EndoGastric Solutions® today announced the publication of a new review article in Therapeutic Advances in Gastroenterology1 that describes the ...
Statistical analysis shows that 2.1% of Hydrus Microstent patients required subsequent invasive glaucoma surgery compared with 6.0% of the cataract surgery-only patients, which represents a clinically meaningful and statistically significant difference. ...
The announcement was made today by Ivantis Inc., a company dedicated to developing new and innovative solutions for glaucoma. SPECTRUM is a patient registry for the Hydrus® Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with mild to moderate primary open-angle glaucoma (POAG) in conjunction with cataract surgery or as a ...
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in AKST6021-211, a phase 2 clinical trial of its proprietary human plasma fraction, GRF6021, administered before and after primary hip or knee arthroplasty, to provide key insights into the ...
DT MedTech, LLC (DTM) announced today that their new Hintermann Series H2 Tibial Assembly component and PE inlay have been successfully implanted by Prof. Beat Hintermann in three patients needing total ankle revision surgery. World-renowned foot and ankle surgeon, Prof. ...